impel neuropharma, inc., is a privately-held, seattle-based company devoted to creating life-changing, innovative therapies for central nervous system (cns) diseases. impel's products are based on a novel nasal drug delivery platform, the pod™ device, that administers drug to the upper nasal cavity in a consistent and predictable manner. impel neuropharma is currently investigating inp104 (pod™ dhe) for acute migraine headache, inp103 (pod™ levodopa) for parkinson's disease, inp105 (pod™ olanzapine) for agitation in schizophrenia and bipolar disorders as well as inp102 (pod™ insulin) for alzheimer's disease in an nih funded trial. impel neuropharma's proprietary pod™ device enables small and large molecule drugs to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. to learn more about impel neuropharma, please visit our website at http://impelnp.com.